Table 3.
In-field tumor response rates of the target lesions after tomotherapy and concurrent capecitabine treatment
| Target lesions | CR | PR | SD | PD |
|---|---|---|---|---|
| Pancreatic mass (n = 15) | 0 (0) | 8 (53.3) | 7 (46.7) | 0 (0) |
| Regional lymph nodes (n = 4) | 0 (0) | 1 (25.0) | 3 (75) | 0 (0) |
| Distant metastasis (n = 7) | 0 (0) | 2 (28.6) | 5 (71.4) | 0 (0) |
| Liver (n = 6) | 0 (0) | 1 (16.7) | 5 (83.3) | 0 (0) |
| Lung (n = 1) | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Overall (n = 26) | 0 (0) | 11 (42.3) | 15 (57.7) | 0 (0) |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease
Numbers in parentheses are percentages